Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4

NCT04246762 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Olokizumab
DRUG: Omeprazole
DRUG: Caffeine
DRUG: Warfarin+ Vitamin K
DRUG: Midazolam

Sponsor

R-Pharm International, LLC

Collaborators

[object Object]
[object Object]